[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Robert Tighe, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100498649","phase-1-macrophage-regulation-of-ozone-induced-lung-inflammation-100498649",false,"NCT05773001","Macrophage Regulation of Ozone-Induced Lung Inflammation","MOLI","Inclusion Criteria:\n\n* Individuals between 18-55 yrs. of age (No subject will be excluded from the study on the basis of gender or ethnicity)\n* Individuals with knowledge of prior respiratory viral infection history allowing them to be segregated into one of three cohorts\n\n  * Cohort 1 - No history of respiratory viral infection (defined as no symptoms consistent with respiratory viral infection nor history of a positive respiratory viral test)\n  * Cohort 2 - Documented mild respiratory viral infection (a positive test, either PCR- or antigen-based) but with mild to no symptoms and no evidence of a lower respiratory tract infection (including no hospitalization, and no oxygen use)\n  * Cohort 3 - History of respiratory viral infection and symptoms\u002Fimaging consistent with a lower respiratory tract infection who have recovered, are \\>6 months out from their infection, and have normal lung function (spirometry with FVC, FEV1 and FEV1\u002FFVC)\n\n    * There will be no maximal period from respiratory viral infection for inclusion in the study, the minimal period will be \\>6 months out from infection\n\nExclusion Criteria:\n\n* Individuals with prior respiratory viral pneumonia who have ongoing respiratory symptoms, are still using supplemental oxygen, or have abnormal lung function\n* Current smokers of tobacco products including e-cigarettes or those with previous smoking history within the prior 5 years\n* Pregnant women and women who are presently lactating.\n* Subjects that have received antibiotic administration or an upper respiratory infection within the previous 4 weeks\n* College and graduate students or employees who are under direct supervision by any of the investigators in this protocol\n* Alcohol or illicit substance abuse\n* Chronic cardio\u002Fpulmonary respiratory disorders or other medical conditions as determined by the investigator\n* Increased airway hyperresponsiveness at baseline as measured by a positive methacholine challenge response (methacholine PC20 FEV1 \\\u003C 4 mg\u002Fml)\n* Subjects will be requested to refrain from antihistamines, nonsteroidal anti-inflammatory agents, antioxidants (e.g. beta-carotene, selenium, and lutein) and supplemental vitamins (e.g. C and E), for 1 week prior to, and during testing.",true,"ALL","18 Years","55 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.",[28],"Respiratory Viral Infection","RECRUITING","2026-05-13",{"date":32,"type":33},"2026-05-15","ACTUAL",{"date":35,"type":33},"2023-05-18",{"date":37,"type":22},"2028-05",{"name":39,"class":40},"Robert Tighe, MD","OTHER",""]